Lyell Immunopharma, Inc. (LYEL) Financials

LYEL Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 750.0 million 95.1 million
2023-09-30 795.0 million 97.4 million
2023-06-30 835.4 million 98.5 million
2023-03-31 880.5 million 96.6 million

LYEL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -40.7 million 8.5 million
2023-09-30 -37.9 million 10.5 million
2023-06-30 -40.1 million 14.2 million
2023-03-31 -47.7 million 13.9 million

LYEL Net Income

No data available :(

LYEL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 546.2 million - 63.2 million
2023-09-30 575.4 million - 58.6 million
2023-06-30 595.7 million - 60.2 million
2023-03-31 612.8 million - 61.8 million

LYEL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 253.1 million
2023-09-30 251.3 million
2023-06-30 250.2 million
2023-03-31 249.6 million

LYEL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 25000 41.6 million 13.2 million -
2023-09-30 195000 43.8 million 15.5 million -
2023-06-30 933000 47.5 million 19.0 million -
2023-03-31 1.5 million 44.6 million 19.3 million -

LYEL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 13000 5.1 million
2023-09-30 25000 5.1 million
2023-06-30 27000 4.5 million
2023-03-31 65000 5.0 million

LYEL

Price: $2.38

52 week price:
1.32
3.97

Earnings Per Share: -0.92 USD

P/E Ratio: -2.25

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 208634

Market Capitalization: 531.1 million

Links: